Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Contemporary Clinical Trials
|
May 1, 2012
Randomization to standard and concise informed consent forms: development of evidence-based consent practices
Mary E Enama, Zonghui Hu, Ingelise Gordon, et al.
Plos One
|
March 14, 2014
Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)
Mary E Enama, Julie E Ledgerwood, Laura Novik, et al.
Plos One
|
September 30, 2014
Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial
Uzma N Sarwar, Laura Novik, Mary E Enama, et al.
Vaccine
|
November 28, 2006
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals
Janie Parrino, Lewis H McCurdy, Brenda D Larkin, et al.
Plos One
|
February 4, 2010
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
Richard A Koup, Mario Roederer, Laurie Lamoreaux, et al.
The Journal of Infectious Diseases
|
May 2, 2013
Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
Julie E Ledgerwood, Kathryn Zephir, Zonghui Hu, et al.
Plos One
|
April 12, 2013
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
Barney S Graham, Mary E Enama, Martha C Nason, et al.
Vaccine
|
March 30, 2007
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
Andrew T Catanzaro, Mario Roederer, Richard A Koup, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 28, 2007
Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
Jorge A Tavel, Julie E Martin, Grace G Kelly, et al.
The Journal of Infectious Diseases
|
November 17, 2006
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
Barney S Graham, Richard A Koup, Mario Roederer, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Contemporary Clinical Trials
|
May 1, 2012
Randomization to standard and concise informed consent forms: development of evidence-based consent practices
Mary E Enama, Zonghui Hu, Ingelise Gordon, et al.
Plos One
|
March 14, 2014
Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)
Mary E Enama, Julie E Ledgerwood, Laura Novik, et al.
Plos One
|
September 30, 2014
Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial
Uzma N Sarwar, Laura Novik, Mary E Enama, et al.
Vaccine
|
November 28, 2006
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals
Janie Parrino, Lewis H McCurdy, Brenda D Larkin, et al.
Plos One
|
February 4, 2010
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
Richard A Koup, Mario Roederer, Laurie Lamoreaux, et al.
The Journal of Infectious Diseases
|
May 2, 2013
Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
Julie E Ledgerwood, Kathryn Zephir, Zonghui Hu, et al.
Plos One
|
April 12, 2013
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
Barney S Graham, Mary E Enama, Martha C Nason, et al.
Vaccine
|
March 30, 2007
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
Andrew T Catanzaro, Mario Roederer, Richard A Koup, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 28, 2007
Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
Jorge A Tavel, Julie E Martin, Grace G Kelly, et al.
The Journal of Infectious Diseases
|
November 17, 2006
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
Barney S Graham, Richard A Koup, Mario Roederer, et al.
Page
of 4